Tesamorelin increased rectus and psoas muscle size by 0.44 and 0.46 cm² in people with HIV and belly fat, but this effect was reduced when considering changes in a growth hormone-related factor.
Scientific Claim
Increases in rectus and psoas muscle total area (0.44 and 0.46 cm²) in tesamorelin responders with HIV and abdominal obesity were observed, but these effects were attenuated when adjusting for insulin-like growth factor-1 changes.
Original Statement
“adjustment for change in IGF-1 explained most of the changes in total muscle area, such that many associations were no longer significant.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The claim accurately describes the attenuation effect observed in the data using 'attenuated' and specifies the adjustment context.
Evidence from Studies
Supporting (1)
The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV